Companies › Medley Therapeutics
1 active drug program in 1 registered trial: 1 Phase 1; Cardiovascular; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| YAP101 (AAV9-Sav-shRNA) AAV9-delivered short hairpin RNA targeting YAP1 to promote cardiac regeneration | YAP1 | Phase 1 | Heart Failure With Reduced Ejection Fraction | Dec 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06831825 | YAP101 (AAV9-Sav-shRNA) | Phase 1 | Heart Failure With Reduced Ejection Fraction | Cardiovascular | Dec 2026 |
–
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.